Herpes simplex virus type 2 (HSV-2) is a risk factor for HIV-1 infection. We characterized HSV-2 serology assay performance in HIV-positive and HIV-negative Africans. Serostatus for HSV-2 and HIV-1 was determined in 493 serum specimens stored from a community HSV-2 prevalence survey in Kampala, Uganda. HSV-2 serology by Focus HerpeSelect ELISA, Biokit HSV-2 rapid assay and Kalon HSV-2 was compared with HSV-2 Western blot (WB) according to HIV-1 serostatus. Sensitivity/specificity was: 99.5%/70.2% for Focus, 97.0%/86.4% for Biokit and 97.5%/96.2% for Kalon. Focus with Biokit confirmation improved sensitivity/ specificity (99.4%/96.8%, respectively). Use of a higher Focus index value cut-off of 2.2 instead of 1.1 increased specificity from 70.2% to 92.4%. Kalon had higher specificity than Focus (P , 0.001). Of commercially available HSV-2 serological assays, Kalon alone, or Focus ELISA followed by Biokit confirmation perform best. Improved HSV-2 assays are needed for HSV-2 and HIV-1 public health activities in Africa.
INTRODUCTION
New biomedical strategies to reduce acquisition and transmission of HIV-1 are needed to complement existing strategies such as behaviour change, condoms and male circumcision. Over the last decade, genital herpes due to herpes simplex virus type 2 (HSV-2) infection has become a major focus for HIV-1 prevention. HSV-2 is the principal cause of genital ulcer disease globally, including in Africa. Antiviral regimens can reduce the duration and frequency of herpes symptoms. The majority of HSV-2 reactivation is subclinical and unrecognized by infected individuals and their clinical providers, 1 -4 thus serology tests are needed for public health initiatives that require identification of those persons with unrecognized HSV-2 infection.
Evidence is accumulating for a synergistic interaction between HSV-2 and HIV-1. 5, 6 Observational data indicate that approximately 85% of HIV-infected persons in Africa are co-infected with HSV-2, and that HSV-2 increases HIV-1 infectiousness and is associated with increased risk of HIV-1 transmission to sexual partners. 5,7 -9 Furthermore, among HIV-1-infected persons, HSV-2 recurrence rate, and the severity and duration of symptoms are increased in persons with CD4 counts less than 200 cells/mm 3 . 5, 7, 10, 11 On the other hand, HSV-2 seroprevalence is 50% among HIV-uninfected populations and is associated with a 2-3-fold increased risk of HIV-1 acquisition. 5, 7, 12 Although recent clinical trials using acyclovir for HSV-2 suppression in HIV-negative, HSV-2 seropositive persons did not show a reduction in HIV-1 acquisition, 13, 14 multiple placebocontrolled, double-blind proof-of-concept trials have demonstrated that HSV-2 antiviral suppression does reduce HIV-1 plasma and genital viral loads. 15, 16 A recent clinical trial found that HSV-2 suppression reduced HIV-1 disease progression, providing an option for delaying initiation of antiretrovirals in persons with intermediate CD4 counts. 7, 17 Two 'gold standard' type-specific serological assays, Western blot (WB) and monoclonal antibody inhibition assays, 18, 19 have been developed based on detection of antibody response to the type-specific gG herpes virus glycoprotein. Several gG-based type-specific commercial serology assays have been developed and some approved by the US Food and Drug Administration (FDA) after testing against the gold-standard WB. 19, 20 One of these, the HerpeSelect HSV IgG ELISA ('Focus'; Focus Technologies, Cypress, CA, USA) is widely used both in the USA and worldwide. The specificity of the test varies by regional background with higher false-positive rates among African compared with American Caucasian cohorts. 20 -22 A second HSV type 2 IgG ELISA ('Kalon'; Kalon Biological Ltd, Surrey, UK; not FDA approved) has been shown to have superior sensitivity to Focus in African sera. 20, 21, 23 A third FDA approved, type-specific assay, Biokit HSV-2 Rapid Assay ('Biokit'; Biokit USA, Lexington, MA, USA; formerly POCkit-HSV-2 from Diagnology), also has high sensitivity and specificity. 19, 20, 24 Biokit can improve the positive predictive value of the Focus assay when used to confirm positive specimens in North American cohorts. 19, 24, 25 Given the performance differences of commercial HSV-2 assays in African populations, additional data are needed to inform recommendations for use of HSV-2 serological assays in the context of future HIV-1 prevention activities. In this study, we tested specimens collected in a Ugandan serosurveillance study by Focus, Kalon and Biokit HSV-2 serological assays using the type-specific HSV WB as a gold standard 21 to determine the sensitivity and specificity of combination testing algorithms and the use of different cut-offs for the EIA tests.
METHODS

Patients and specimens
Sera were collected from 1126 adults in the Kawempe Division in Kampala, Uganda for a 2004 'Seroprevalence and incidence of genital herpes in Uganda' survey performed by the Department of Medical Microbiology, Makerere University, Kampala. 26 Of 1124 individuals in this cohort with questionnaire data collected, 786 (70%) were women, 546 (48%) were less than 25 years of age and 599 (53%) were married. Local testing with first generation Focus yielded 657 positive (index .3.4), 193 low positive (index between 1.1 and 3.4) and 276 negative (index ,0.9) results. A subset of stored samples were sent to Seattle including all low positive samples (n ¼ 193) and a subset of 'high positive' or negative samples (n ¼ 150 for each category). These specimens were made anonymous before shipping to the University of Washington (UW) for more extensive HSV-2 and HIV-1 serology testing.
Laboratory assays -HSV-2
All 493 specimens sent from Kampala were evaluated at the University of Washington Virology Laboratory using commercial tests performed according to kit instructions; WB was performed as described previously. 27 'Equivocal' results were scored if bands on the HSV-2 blot were insufficient in number or intensity to qualify as a positive result after preabsorption against HSV-1 antigens. Technicians were blinded to HIV status and results of other assays, whether performed in Seattle or Kampala. Results were analysed only after all testing was completed.
Focus testing in Seattle utilized a second generation kit modified by the company to improve specificity. Focus first and second generation and Kalon assays have the same manufacturer recommended index value cut-offs for test interpretation: index values ,0.9 are negative, .1.1 are positive, and index values 0.9-1.1, inclusive, are equivocal. Index values between 1.1 and 3.4 were classified for this study as 'low positive' and .3.4 as 'high positive'. Biokit test results were recorded as positive when the test spot was clearly coloured red or pink, and negative when the test spot was faint or without colour.
Laboratory assays -HIV-1
Sera were tested by three different HIV-1 ELISAs: Bio-Rad Genetic Systems TM HIV-1/HIV-2 plus O ELISA (Bio-Rad Laboratories, Redmond, WA, USA), Abbott HIVAB TM HIV-1/ HIV-2 (rDNA) ELISA (Abbott Laboratories, Abbott Park, IL, USA) and Vironostikaw HIV-1 Microelisa System (bioMerieux, Inc, Durham, NC, USA). Sera reactive by any single ELISA assay was confirmed utilizing the Bio-Rad Genetic Systems TM HIV-1 WB (Bio-Rad Laboratories). For this analysis, samples with positive results on the HIV-1 WB were identified as HIV-1 positive. Samples were identified as HIV-1 negative if ELISA results were uniformly negative or the WB was negative after initial reactive or contradictory ELISA results.
Statistical analyses
Sensitivity and specificity of the different HSV-2 serological tests and combinations were computed with HSV-2 WB as the 'gold standard', using manufacturer cut-offs for positivity. Positive and negative predictive values were computed for the observed HSV-2 prevalence and a range of possible population HSV-2 seroprevalences.
Samples evaluated in Seattle included all those with a Focus low positive test result in Kampala and a proportion of those from other Focus result categories (i.e. negative, equivocal and high positive) based on tests performed in Kampala. This represented a non-random selection of specimens from the original Kampala study set. Therefore, we inferred testing results for samples not tested in Seattle as being confirmed by WB and Biokit in the same proportions as tested samples within each Focus category. HSV-2 confirmation rates among the samples were estimated based on Focus testing in Kampala (using first generation Focus), subsequent agreement by Focus testing in Seattle (with second generation Focus), and further confirmation of Seattle Focus testing by WB testing in Seattle. The corresponding uncertainty of these confirmation rates was estimated according to the number of results received. Confidence intervals for accuracy rates were computed using the normal approximation to the binomial. Interim confidence intervals were computed assuming low and high WB confirmation rates in untested samples using the anticipated variability based on tested samples. Final confidence intervals include uncertainty in both the number of samples confirmed and in the estimated confirmation rates of those not confirmed.
An analysis of Focus serology results was initially performed using the manufacturer's index cut-off for Focus positivity described above. In a subsequent analysis, an alternate index cut-off for Focus positivity was optimized to this Ugandan study population using receiver-operator curves (ROC) 28 with HSV-2 status by WB as the gold standard. For this analysis, Focus index values for each category of WB result for Kampala samples not tested in Seattle were simulated following the normal distribution and using mean and standard deviation of the observed Focus index values on the log10 scale. This was done to develop data-sets representative of the population. Simulations for the 633 untested sera were performed three times and ROC curves were built for each 'augmented' data-set. An alternate index value cut-off was chosen that maximized the sum of sensitivity and specificity by choosing the point nearest the top left corner of the ROC curve, thus treating false-positives and false-negatives equally. Confidence intervals for sensitivity and specificity were again computed using the new Focus cut-off, as well as updated positive and negative predictive values over a range of potential population prevalence rates. Focus test results reflecting the manufacturer's index cut-off of 1.1 and results reflecting the ROC optimized cut-off are referred to as 'Focus 1.1' and 'Focus 2.2', respectively.
ROC curves were created in a similar fashion for Kalon results to assess optimal cut-offs with the manufacturer's and optimized cut-offs found to provide similar results. Therefore, manufacturer's cut-offs for Kalon were used in all analyses.
McNemar's test was performed to compare sensitivity and specificity of Kalon versus Focus (using either index cut-off ) and Focus with positive results confirmed by Biokit. Only samples tested by relevant methods in Seattle were used in these calculations; assumed rates in samples tested only in Kampala were not included. Since the samples sent to Seattle were heavily weighted with low positive results based on Kampala Focus findings, the accuracy measures apply to a population that is not representative; however, the comparison remains valid as it is based on completed tests and is preferable to assuming that confirmation rates would be similar to nontested samples. All subjects regardless of HIV-1 status were included in the analysis, with the analysis repeated using only HIV-1-infected participants.
Human subjects review
The Joint Clinical Research Centre (JCRC) and Case Western University Institutional Review Boards reviewed and approved the protocol for the Kampala seroprevalence survey. Subsequently, the JCRC, Uganda National Council for Science and Technology and UW IRBs approved HSV-2 and HIV-1 testing of anonymous specimens at the UW. (Table 1) .
RESULTS
After excluding WB equivocal samples and adjusting proportions to account for sampling from the original community survey cohort, an ROC analysis of Focus testing results yielded an optimum positive index value cut-off of 2.2 (test results using this cut-off are referred to as 'Focus 2.2') for each augmented data-set instead of the manufacturer recommended cut-off of 1.1 (test results using this cut-off are referred to as 'Focus 1.1').
We evaluated sensitivity and specificity of HSV-2 assays individually and in combination relative to WB ( Table 2 ). In this analysis, Focus 1.1 had the highest sensitivity 99.5%, and lowest specificity 70.2% and Biokit had the highest specificity 97.0% and lowest sensitivity 86.4%. Biokit confirmation of Focus 1.1 positive results improved Focus sensitivity and specificity to 97.5% and 96.2%, respectively. These figures are similar to results from Kalon testing, which had 99.4% sensitivity and 96.8% specificity with the 1.1 cut-off. After optimizing the index value cut-off for this Ugandan population, Focus 2.2 maintained high sensitivity (96.4%), and had markedly increased specificity (92.4%) compared with Focus 1.1 (70.2%). Kalon's higher specificity as compared with Focus 1.1 was statistically significant (P , 0.001). Focus 1.1 had a higher sensitivity over Kalon that was borderline significant (P ¼ 0.063).
Biokit confirmation of Focus positive results, using either a Focus cut-off of 1.1 or 2.2, resulted in a substantial number of samples (111 using Focus 1.1 plus Biokit and 33 using Focus 2.2 plus Biokit) being deemed 'indeterminate' and excluded from the analysis due to a Focus positive result being followed by a negative Biokit result. These samples were mainly among the low positives, so their exclusion may obscure the comparison between these tests.
Sensitivity and specificity values for each assay were used to calculate positive (PPV) and negative predictive values (NPV) as a function of HSV-2 prevalence (Figure 1 2.2 þ Biokit; however, statistical comparisons were not performed for differences in predictive values since these values depend on accurate estimation of the seropositivity prevalence, something we could not confidently estimate given the nonrandom selection of this subset of samples. We also evaluated HSV-2 serological assay performance by HIV-1 serostatus. Among the 467 samples with definitive HSV-2 WB results, using HIV-1 WB as the gold-standard, we identified 399 (85.4%) HIV-1 seronegative, 57 (12.2%) HIV-1 seropositive and 11 HIV-1 WB indeterminate in this cohort (Table 3 ). Sensitivity and specificity of each HSV-2 assay for HIV-1-seropositive and HIV-seronegative cohorts generally paralleled results for the full cohort (data not shown).
Statistical comparisons between serological tests in the
HIV-specific subsets could not be performed either because results were identical between tests or because all subjects were classified as positive or negative by one or both tests.
DISCUSSION
Simple and accurate HSV-2 serological assays for African populations are needed. Such assays will be of particular importance if HSV-2 suppression to delay HIV-1 disease progression is to be considered for implementation. Our comparison of HSV-2 serological assays from samples of a community-based HSV-2 serosurveillance study in Kampala, Uganda indicates that as a single assay, Kalon had the best overall sensitivity and specificity. However, if Biokit is used to confirm Focus 1.1 positive results, the sensitivity and specificity of this combination was comparable to the Kalon assay. The addition of Biokit confirmation is analogous to current diagnostic testing for syphilis using a highly sensitive screening test (e.g. VDRL or RPR for syphilis) followed by a highly specific confirmatory (i.e. treponemal-specific) assay. However, the use of Biokit confirmation of Focus positives does add to the total cost of the evaluation.
In lieu of confirmation with Biokit or another test, studies have suggested that Focus assay performance may be improved in African populations by increasing the index value cut-off for a positive result. 20 -22,29,30 Our findings corroborate that an optimized Focus index value cut-off of 2.2 was associated with higher specificity than the standard cut-off of 1.1 (92.4% versus 70.2%) with only modest reduction in sensitivity (96.4% versus 99.5%). Studies involving other African populations may help further define a more universal cut-off that could be applied to Focus testing in Africans. However, a practical consequence of an adjusted index cut-off will be an increase in the proportion of sera with HSV-2 testing results below the low positive cut-off, some of whom will be individuals in the process of seroconverting, thus requiring specific counselling messages and follow-up testing.
Notably, the study samples were a selected subset of the original Kampala community-based cohort with a bias toward including specimens with a Focus result in the 'low positive' range. Historically, such samples have been an important source of discrepancy for different HSV-2 serological assays and oversampling these samples provided increased power to discern differences in how the Kalon and Biokit assays performed on these. In order to ensure that our results appropriately reflected the original study population, we implemented statistical adjustments to account for this biased sample selection. Although development of more robust assays will be the best approach for HSV-2 testing in Africa, our data support some practical options for using existing commercial HSV-2 serological assays for HSV-2 diagnosis and management, and for development of HIV-1 prevention strategies in Africa: Kalon assay alone, a combination of Focus 1.1 and Biokit, and Focus 2.2 all demonstrate comparable sensitivity and specificity. However, each option is accompanied by a different tradeoff: Focus 1.1 had higher rates of false-negative findings (specificity 70.9%) in HIV-1-infected persons; Focus plus Biokit would have higher testing cost; and Focus 2.2 leaves a higher proportion of subjects who have recently HSV-2 seroconverted in need of subsequent evaluations to clarify their HSV-2 status. Furthermore, the predictive value of any assay will need to be systematically assessed, particularly in the context of high HSV-2 prevalence such as would be encountered among HIV-infected populations. These are all important practical considerations that will impact on which assay is selected for HSV-2 testing in Uganda and elsewhere in Africa. Regional and population differences may require assessment prior to implementation of HSV-2 serological screening programmes.
In summary, HSV-2 suppression can provide clinical benefits to HIV-1-infected persons. While our results indicate that existing commercial tests can be used, either by using the Kalon EIA with the manufacturer's cut-off, by increasing the cut-off for the Focus EIA or by confirming positive assays with Biokit. Additional HSV-2 serological assays with higher sensitivity and specificity, ideally in a point-of-care format, for African populations are needed so that as effective HSV-2 interventions are identified, such as better therapeutic drugs for HSV-2 and ultimately an HSV-2 vaccine, they can be implemented both for HSV-2 and HIV-1 prevention. 
